NASDAQ:CLRB Cellectar Biosciences (CLRB) Stock Price, News & Analysis $0.32 0.00 (-0.91%) Closing price 03/10/2025 04:00 PM EasternExtended Trading$0.31 -0.01 (-1.94%) As of 03/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Cellectar Biosciences Stock (NASDAQ:CLRB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cellectar Biosciences alerts:Sign Up Key Stats Today's Range$0.31▼$0.3450-Day Range$0.24▼$0.3552-Week Range$0.22▼$4.17Volume1.29 million shsAverage Volume1.69 million shsMarket Capitalization$14.52 millionP/E RatioN/ADividend YieldN/APrice Target$17.67Consensus RatingModerate Buy Company OverviewCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Read More… Remove Ads Cellectar Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCLRB MarketRank™: Cellectar Biosciences scored higher than 44% of companies evaluated by MarketBeat, and ranked 596th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCellectar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCellectar Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Cellectar Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.59) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cellectar Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.17% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectar Biosciences has recently decreased by 0.85%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.17% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectar Biosciences has recently decreased by 0.85%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News SentimentN/A News SentimentCellectar Biosciences has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cellectar Biosciences this week, compared to 1 article on an average week.Search Interest12 people have searched for CLRB on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.MarketBeat Follows5 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Cellectar Biosciences is held by institutions.Read more about Cellectar Biosciences' insider trading history. Receive CLRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CLRB Stock News HeadlinesCellectar Biosciences (NASDAQ:CLRB) Coverage Initiated by Analysts at StockNews.comMarch 11 at 1:31 AM | americanbankingnews.comCellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025March 5, 2025 | globenewswire.comThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driving a hidden gold market boom. Garrett Goggin, a renowned precious metals expert with 20+ years of experience, reveals 5 explosive investment opportunities set to explode in this new era. Backed by triple-digit returns in 2024, Garrett’s insights show you how to position yourself for wealth in 2025. Don’t wait—these opportunities can disappear fast!March 11, 2025 | Golden Portfolio (Ad)StockNews.com Begins Coverage on Cellectar Biosciences (NASDAQ:CLRB)March 3, 2025 | americanbankingnews.comCellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comCellectar faces Nasdaq delisting over share price ruleFebruary 3, 2025 | msn.comCellectar Biosciences files to sell 19.22M shares of common stock for holdersJanuary 30, 2025 | markets.businessinsider.comCellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare ConferenceJanuary 13, 2025 | finance.yahoo.comSee More Headlines CLRB Stock Analysis - Frequently Asked Questions How have CLRB shares performed this year? Cellectar Biosciences' stock was trading at $0.2990 at the beginning of the year. Since then, CLRB stock has increased by 5.4% and is now trading at $0.3151. View the best growth stocks for 2025 here. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $0.10. When did Cellectar Biosciences' stock split? Shares of Cellectar Biosciences reverse split before market open on Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Cellectar Biosciences' major shareholders? Cellectar Biosciences' top institutional shareholders include ADAR1 Capital Management LLC (1.27%), Squarepoint Ops LLC (1.13%), Bank of America Corp DE (0.45%) and JPMorgan Chase & Co. (0.40%). View institutional ownership trends. How do I buy shares of Cellectar Biosciences? Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectar Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Hudbay Minerals (HBM), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings11/07/2021Today3/11/2025Next Earnings (Estimated)3/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLRB CIK1279704 Webwww.cellectar.com Phone(608) 441-8120Fax608-441-8121Employees10Year FoundedN/APrice Target and Rating Average Stock Price Target$17.67 High Stock Price Target$28.00 Low Stock Price Target$12.00 Potential Upside/Downside+5,506.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,770,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-191.22% Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.96) per share Price / Book-0.33Miscellaneous Outstanding Shares46,080,000Free Float44,375,000Market Cap$14.52 million OptionableOptionable Beta0.96 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:CLRB) was last updated on 3/11/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.